• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Assay to Diagnose Leishmaniasis

sharon sanders

Editor-in-Chief & President
[SIZE=-1] Clinical and Vaccine Immunology, December 2007, p. 1592-1595, Vol. 14, No. 12
1071-412X/07/$08.00+0 doi:10.1128/CVI.00313-07
Copyright ? 2007, American Society for Microbiology. All Rights Reserved. [/SIZE]
Use of a Newly Developed β-Mercaptoethanol Enzyme-Linked Immunosorbent Assay To Diagnose Visceral Leishmaniasis in Patients in Eastern Sudan<sup>
dtri.gif
</sup>


Durria Mansour, Elfadil M. Abass, Mohamed el Mutasim,<sup>
dagger.gif
</sup> Abdelhafeiz Mahamoud, and Abdallah el Harith<sup>*</sup>
Ahfad University for Women, P.O. Box 167, Omdurman, Sudan
Received 26 July 2007/ Returned for modification 12 September 2007/ Accepted 2 October 2007


<!-- ABS --> Corroboration of serology results is essential for restricting<sup> </sup>the risk of inappropriate antileishmanial prescription. A direct<sup> </sup>agglutination test (DAT) and a recently developed β-mercaptoethanol-modified<sup> </sup>enzyme-linked immunosorbent assay (β-ME ELISA) based on<sup> </sup>the use of antigen prepared as described for the DAT were applied<sup> </sup>to 416 sera from two Sudanese populations with and without clinical<sup> </sup>evidence of visceral leishmaniasis (VL). Of 285 sera with the<sup> </sup>lowest antileishmanial DAT titers (
le.gif
1:100 to 1:1,600), 270 (94.7%)<sup> </sup>scored comparable minimum β-ME ELISA absorbance values<sup> </sup>(
le.gif
0.1 to 0.26). In 117 sera that demonstrated the highest DAT<sup> </sup>titers (1:12,800 to
ge.gif
1:25,600), 86 (73.5%) scored maximum (0.81<sup> </sup>to
ge.gif
1.35) and 30 (25.6%) medium (0.27 to 0.80) β-ME ELISA<sup> </sup>absorbance values. VL diagnosis was established for 142 (44.1%)<sup> </sup>patients in the VL-symptomatic group (n = 322), based on positive<sup> </sup>microscopy for Leishmania donovani in lymph node aspirates or<sup> </sup>positive DAT (titer,
ge.gif
1:3,200). Of the 125 sera from the symptomatic<sup> </sup>patients for whom microscopy was positive for VL, 111 (88.8%)<sup> </sup>had comparable positive DAT and β-ME ELISA readings. In<sup> </sup>all 17 sera from the symptomatic DAT-positive patients for whom<sup> </sup>leishmaniasis was not established by microscopy but who responded<sup> </sup>favorably to antileishmanial therapy, absorbance values (
ge.gif
0.27)<sup> </sup>indicative of VL were obtained by β-ME ELISA. Of 197 symptomatic<sup> </sup>patients for whom microscopy was negative for VL, 172 (87.3%)<sup> </sup>tested negative in β-ME ELISA and 180 (91.4%) in DAT. Based<sup> </sup>on the high reliability demonstrated here for VL detection,<sup> </sup>β-ME ELISA fulfills the requirement of confirming DAT results<sup> </sup>in patients manifesting suspected VL.

http://cvi.asm.org/cgi/content/abstract/14/12/1592
 
Back
Top